Immunology News

Axcella announced initiating patient screening for the EMMPOWER phase 2 clinical trials of AXA1665 for reduction in risk for recurrent overt hepatic encephalopathy, according to a press release.

VIR-2218, an investigational small interfering ribonucleic acid therapeutic, was well tolerated in patients for the treatment of chronic hepatitis B virus, according to research presented at the International Liver Congress.

Brii Biosciences, Vir Biotechnology and VBI Vaccines announced the first patient dosed in a phase 2 trial evaluating combination therapy for the treatment of patients with chronic hepatitis B infection, according to a press release.

Discontinuation of long-term nucleos(t)ide analogues has the potential to induce durable immune control and functional cure in patients with e antigen-negative, or HBeAG, chronic hepatitis B, according to a presenter at The Digital International Liver Congress.

HOUSTON — Researchers found no differences in outcomes between liver transplant recipients with a penicillin allergy label and matched controls, according to findings presented at the American College of Asthma, Allergy & Immunology Science Meeting.

SAN ANTONIO — The National Liver Congress will convene October 25th, providing a broad scientific program and exhibit of products and services important for all practitioners involved in the care of patients with liver disease.

The American Association for the Study of Liver Diseases Foundation has granted $3.42 million in research and career development awards to 29 researchers and clinicians to conduct liver disease research and undergo advanced hepatology training.

Foreign-born women of reproductive age living in the United States reported significantly lower rates of hepatitis B virus screening and vaccination compared with women of the same age born in the U.S., according to recently published research.

The FDA has issued an update to its safety communication regarding the risk for infection associated with the design of the Pentax ED-3490TK duodenoscope.

BiomX recently announced the acquisition of RondinX to expand the company’s pipeline with novel microbial targets for the treatment of liver disease and inflammatory bowel disease, according to a press release.